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Purpose: Downregulation of metallothionein (MT) genes has been reported in several tumors with discrepant
results. This study is to investigate molecular mechanism of MT gene regulation in colon cancer which is
characterized by tumor suppressor gene alterations.
Experimental design: Integral analysis of microarray data with loss of heterozygosity (LOH) information was
employed. Quantitative real-time PCR and immunohistochemistry were used to validate MT isoform expres-
sion in colon cancer tissues and cell lines. The effects of MT1F expression on RKO cell survival and tumorigen-
esis was analyzed. Bisulphite sequencing PCR (BSP) and methylation-speciﬁc PCR were employed to detect
the methylation status of the MT1F gene in colon cancer tissues and cell lines. DNA sequencing was used to
examine the LOH at the MT1F locus.
Results: MT1F, MT1G, MT1X, and MT2A gene expression was signiﬁcantly downregulated in colon cancer tis-
sue (pb0.05). Exogenous MT1F expression increased RKO cell apoptosis and inhibited RKO cell migration, in-
vasion and adhesion as well as in vivo tumorigenicity. Downregulation of MT1F gene in majority of human
colon tumor tissues is mainly through mechanism by loss of heterozygosity (p=0.001) while CpG island
methylation of MT1F gene promoter region was only observed in poorly differentiated, MSI-positive RKO
and LoVo colon cancer cell lines.
Conclusions:MT1F is a putative tumor suppressor gene in colon carcinogenesis that is downregulated mainly
by LOH in colon cancer tissue. Further studies are required to elucidate a possible role for MT1F downregula-
tion in colon cancer initiation and/or progression.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Despite increased detection in recent years, colon cancer re-
mains a major cause of mortality, representing the third most
fatal malignancy in the world [1,2]. Colon cancer arises as a re-
sult of the accumulation of genetic and epigenetic changes that
transform normal colon epithelium into adenocarcinoma [3].
Chromosomal instability, which is characterized by abnormal
chromosome number and loss of heterozygosity (LOH), appears
to play a major role in colon cancer pathogenesis [4], resultingal Surgery, Shanghai Jiaotong
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l rights reserved.in altered tumor suppressor gene (TSG) and oncogene expres-
sion and subsequent tumor progression [5]. Genome-wide LOH
scanning and reﬁned mapping of candidate loci revealed nine
loci as having high LOH frequencies in sporadic colon cancer
[6]. However, the contribution of gene-speciﬁc alterations in
colon cancer progression remains to be fully elucidated. In par-
ticular, the role of TSGs has yet to be explored.
Xiao et al. [7] reported that 33% of Chinese colon cancer patients
had a deletion hotspot of chromosome 16q11.2–21. Further reﬁned
mapping revealed that 16q13.1, which contains metallothionein
(MT) genes, had a high LOH frequency. MTs are lowmolecular weight
(6–7 kDa) cysteine-rich proteins [8]. HumanMT proteins are encoded
by a family of genes containing two ubiquitous isoforms, MT1 and
MT2, and two tissue-speciﬁc isoforms, MT3 and MT4; MT3 and MT4
expression is restricted to the brain and squamous epithelia of the
skin and tongue, respectively [9–11].
Discrepant results regarding MT protein expression in human can-
cers have been reported. MT expression was upregulated in breast,
lung, kidney and pancreatic cancers, and it was often correlated
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tocellular, gastric, central nervous system, and thyroid cancers, MT
expression is downregulated, inversely correlated, or unrelated to
mortality [8]. In some studies, MT was repressed in primary colon
cancer and metastatic lesions, and its expression was inversely corre-
lated with tumor development [12–14]. Other studies reported that
MT expression was associated with tumor inﬁltration, Dukes' stage,
and poor survival [15–17]. Furthermore, microarray data revealed
that theMT1F gene was downregulated in normal-adenoma–carcino-
ma sequence of colon tissues [18]. In colon cancer cell lines, MTmRNA
isoform expression was basally repressed [19]. Differential regulation
ofMT gene isoforms in various tumors may account for these discrep-
ant results [8].
The present study aimed to further explore MT isoform expression
in colon cancer. Speciﬁcally, the expression proﬁle of MT genes was
determined in colon cancer tissues as well as colon cancer cell lines
using integral analysis of LOH loci and previously obtainedmicroarray
data [20] that was subsequently validated by quantitative real-time
polymerase chain reaction (QRT-PCR). Because the MT1F gene was
downregulated in normal-adenoma–carcinoma sequence of colon tis-
sues [18], this study speciﬁcally analyzed its protein expression using
immunohistochemistry and tissue microarrays (TMAs). The inﬂuence
of MT1F expression on RKO colon cancer cell growth, migration, inva-
sion and tumorigenicity was also analyzed.
2. Materials and methods
2.1. Clinical samples and cell lines
This study was approved by the Institutional Review Board of the
Shanghai First People's Hospital. Tissue samples were collected from
40 colon cancer patients (21 male and 19 female; median age of
67.5 y, range 48–87 y), who had undergone tumor resection without
receiving preoperative therapy, at the General Surgery Department.
The clinicopathologic parameters of each patient were shown in
Table S1. The fresh cancerous mucosa and adjacent normal mucosa
(10 cm distant from the original tumor site) were immediately frozen
in liquid nitrogen and stored at−80 °C until DNA/RNA extraction for
quantitative real time PCR (QRT-PCR). Tumor stage classiﬁcation was
carried out as previously described [21]. Tissue samples for Affyme-
trix HG U133 Plus 2.0 GeneChip experiments or TMA construction
were harvested as previously described [20,22].
Six human colon cancer cell lines, RKO, HCT116, HT29, SW620,
CW-2 and LoVo cells, were obtained from the Cell Resource Center
of Shanghai Institutes for Biological Sciences, Type Culture Collection
of the Chinese Academy of Sciences (Shanghai, PR China). The cells
were cultured under conditions suggested by the vendors.
2.2. Laser capture microdissection (LCM) microarray analysis
Tissue sample harvest, LCM, RNA extraction, T7 ampliﬁcation, and
microarray hybridization were undertaken as described previously
[20]. Microarray data was analyzed using GeneChip Operating Soft-
ware (Affymetrix, Santa Clara, CA, USA). Expression values and rela-
tive expression values (Signal Log Ratio, Change) were calculated
according to Affymetrix Statistical Algorithms Descriptions. The
Gene Set Enrichment Analysis was performed using Onto-Express at
the website http://vortex.cs.wayne.edu/Projects.html. Genes with a
signal log ratio≤−1 were considered downregulated. Finally, the in-
tegration of downregulated genes with LOH loci was performed to
identify new TSGs.
2.3. QRT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen) after
which cDNA was produced from 1 μg RNA using an A3500 reverse-transcription PCR System (Promega Corporation, Madison, WI,
USA). An aliquot of diluted cDNA equivalent to 10 ng total RNA was
used for QRT-PCR analysis employing the ABI Prism 7500 system
(Applied Biosystems Inc., Foster City, CA, USA) and primers speciﬁc
for each MT isoform [23]. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as an endogenous control; the primers
were sense 5′-GTCCACCACCCTGTTGCTGTA-3′ and antisense 5′-
CTTCAACAGCGACACCCACTC-3′. QRT-PCR reactions were repeated
in triplicate using a 2×SYBR Green PCR Master Mix (Applied Biosys-
tems) and previously reported ampliﬁcation conditions [24]. The
fold change (2−ΔΔCt) in each tumor was compared with paired
non-tumorous tissue.2.4. TMA construction and immunohistochemistry
TMA construction was undertaken as previously reported [22].
Brieﬂy, parafﬁn-embedded TMA sections were dewaxed and rehy-
drated before antigen retrieval was carried out. Immunolabeling
was carried out using a mouse anti-MT monoclonal antibody
(ab12228, Abcam, Cambridge, United Kingdom), which is speciﬁc
for both MT1 and MT2 isoforms, diluted 1:200. Then, the sections
were incubated with an anti-mouse or anti-rabbit secondary antibody
conjugated to horseradish peroxidase (HRP; DAKO Envision System,
DAKO, Carpinteria, CA, USA), and then 3,3′-diaminobenzidine
(DAB). The pattern of MT staining was also characterized as both cy-
toplasmic and nuclear distribution as previously described [13,14,16].
MT expression was evaluated by two pathologists independently,
according to the intensity of the color reaction and the number of
positive cells as described by Dziegiel et al. [16].2.5. Transfection of MT1F in colon cancer cell lines
Gene-speciﬁc primers for cloning MT1F were designed (Table S2)
and MT1F cDNA was ampliﬁed by PCR then subcloned into pEGFP-C1
(Invitrogen), generating pEGFPC1-MT1F, which was veriﬁed by se-
quencing. RKO cells (5×105 per well) were seeded in 6-well plates
and cultured to 60–70% conﬂuence, after which they were transiently
transfected with pEGFPC1-MT1F or empty vector controls using Lipo-
fectamine 2000 (Invitrogen). For stable transfectants, medium was
replaced after 24 h with G418-containing medium (400 μg/mL;
Gibco/Life Technologies, Gaithersburg, MD, USA). After 2 weeks, colo-
nies with ﬂuorescence were expanded. MT1F expression was con-
ﬁrmed using QRT-PCR or Western blot analysis using the anti-MT
monoclonal antibody.2.6. Western blot analysis
Proteins from 40 paired frozen colon tumor and adjacent normal
tissue samples were extracted using Radio Immunoprecipitation Assay
(RIPA) lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, and 0.1% SDS) with phenylmethanesulfonyl
ﬂuoride (17.4 μg/μL) and a protease inhibitor cocktail (0.89 μg/μL,
Sigma-Aldrich). Equivalent amounts of protein were separated on
SDS-polyacrylamide gels followed by transfer to polyvinylidene
diﬂuoride membranes, which were blocked in 5% fat-free milk with
TBS-Tween-20 at room temperature for 1 h, followed by incubation
with either the mouse anti-MT monoclonal antibody (1:500) or anti-
β-actin monoclonal antibody (1:5000, Epitomics, California, USA) for
2 h at room temperature. Following incubation with a goat-anti-rabbit
IgG (H+L) HRP-conjugated secondary antibody (1:5000, Santa Cruz
or 1:1000, Promega, Wisconsin, USA), the blots were visualized using
enhanced chemiluminescence (Pierce Biotechnology, Inc., Rockford,
USA) and exposure to Syngene GBOX/iCHE gel imaging and analysis
systems.
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Exponentially growing RKO, RKO-pEGFPC1, and RKO-pEGFPC1-
MT1F cells were trypsinized and re-suspended in EMEM supplemen-
ted with 10% FBS, and then seeded onto 12-well plates (6×104 cells
per well). The cells were incubated for 7 days, and the number of liv-
ing cells in each well was determined daily using a CASY DT Cell
Counter (Innovatis AG, Reutlingen, Germany). The experiments
were independently repeated three times.
Colony formation was determined by preparing single cell suspen-
sion solutions and seeding 35-mm dishes with 500 cells. After cells
were incubated for 12 days, the colonies were washed twice with
PBS, ﬁxed with pure methanol in −20 °C for 30 min, and stained
with crystal violet for 10 min. Stained colonies were counted, and
the plates were photographed. All experiments were performed in
triplicate.
2.8. Migration, invasion, and adhesion assays
The migration assay was performed using 24-well Boyden cham-
bers with polycarbonate membranes of 8 μm pore size (Corning Inc.,
New York, USA). For the invasion assay, the CytoSelect™ Cell Invasion
Assay Kit (Cell Biolabs, Inc., San Diego, CA) was used according to the
manufacturer's protocol. Cells were cultured for 12 h in serum-free
medium. A cell suspension containing 5×105 cells/mL in serum-free
media containing 0.1% bovine serum albumin (BSA) was prepared;
200 μL was added to the upper chamber and 500 μL media with 20%
FBS was added to the lower chamber. After 48 h for the migration
assay and 72 h for the invasion assay, the incubation was terminated,
and the cells bound to the lower surface of the membrane were ﬁxed
with 95% ethanol and stained with crystal violet. The photographs
were taken under high magniﬁcation with a microscope (Nikon,
Tokyo, Japan).
Cell adhesion was determined using the CytoSelect™ 48-well Cell
Adhesion Assay Kit (Cell Biolabs) following the recommended proto-
col. A cell suspension containing 0.1×106 cells/mL was prepared in
serum-free media, and 150 μL was added to each well. After incuba-
tion at 37 °C for 90 min, each well was washed 4 times with 250 μL
PBS and incubated with 200 μL crystal violet for 10 min at room tem-
perature. After the cells were washed 4 times with 500 μL deionized
water, the wells were air-dried for 30 min.
For quantitative analysis of each experiment, the crystal violet was
dissolved in 200 μL extraction solution per well, and the absorbance
was measured at 590 nm in a plate reader (Bio-Rad, Hercules, CA,
USA). All experiments were done in triplicate.
2.9. Apoptosis and cell cycle analysis
Cell cycle progression and apoptosis were analyzed using the
Annexin V-FITC Apoptosis Kit (BD Biosciences, Palo Alto, CA, USA).
After a 48 h transfection, subconﬂuent cells underwent overnight
serum starvation after which they were harvested, rinsed with PBS,
and ﬁxed in 70% ethanol for 1 h at 4 °C. Apoptosis rates were deter-
mined using a FACSCalibur ﬂow cytometer (BD Biosciences). At
least 1×104 cells were captured in each sample.
Total DNA was extracted from cells using an Apoptosis DNA Lad-
der Detection kit (KeyGen Biotech., Nanjing, China), according to
the manufacturer's recommendation. DNA fragments were visualized
under ultraviolet light in contrast to a DNA marker (DL2000™,
TaKaRa Bio).
2.10. Tumorigenicity in nude mice
Animal studies were carried out in accordance with the guide-
lines established by the Shanghai Resource Center of Laboratory
Animal, Chinese Academy of Science. Six 4- to 6-week old (18 to20 g) BALB/c nu/nu mice per group were subcutaneously injected
into the right ﬂank with 5×106 cells in 0.25 mL PBS. The mice
were sacriﬁced on day 21 after tumor implantation, and tumor
weight and volume were quantiﬁed. A sliding caliper was used
to measure the size of tumors, and the volume of tumors was cal-
culated using the following formula: width2×length×0.5.
2.10.1. Isolation and bisulﬁte treatment of genomic DNA and bisulﬁte
sequencing
Genomic DNA was isolated from cell lines and tissue samples
using the AxyPrep genomic DNA Miniprep kit (Axygen Biosciences,
Union City, CA, USA) according to the manufacturer's protocol. Cell
lines were grown for 72 h in the presence or absence 10 μmol/L of
5-Aza-2′-deoxycytidine (5-Aza-dC), a known DNA methyltransfer-
ase inhibitor (Sigma-Aldrich), before they were harvested for
DNA or RNA extraction. DNA (1 μg) underwent bisulﬁte conversion
using the MethylCode Bisulﬁte Conversion Kit (Invitrogen). In
brief, CT Conversion Reagent was added to the DNA sample and
the following PCR reaction was undertaken: 98 °C for 10 min,
64 °C for 2.5 h, and 4 °C for up to 20 h. The DNA was puriﬁed in
Binding Buffer and incubated in Desulphonation Buffer for 20 min
at room temperature. After Wash Buffer precipitation, the acquired
bisulﬁte-treated genomic DNA was dissolved in 10 μL Elution
Buffer.
The methylation status of all colon cancer cell lines was analyzed
by direct bisulﬁte sequencing of the MT1F promoter. The 5′ region of
the MT1F gene was ampliﬁed using the following primers: sense, 5′-
GGGATTTTAGGAAAGGTTTAGTTGT-3′ and antisense, 5′-CTCTCAAA
ATCTTAACCAAAAAAAA-3′. The fragment covered 41 CpG sites and
was ampliﬁed using Platinum Taq DNA polymerase High Fidelity
(Invitrogen). PCR conditions were as follows: 95 °C for 5 min; 40 cy-
cles of 95 °C for 30 s, 53 °C for 30 s and 72 °C for 40 s; and a ﬁnal ex-
tension of 10 min at 72 °C. The PCR products were gel-puriﬁed with
AxyPrep DNA Gel Extraction Kit (Axygen Biosciences), and cloned
into pMD18-T (TA) (Takara Bio). The plasmid DNA isolated from
eight clones of each PCR product was sequenced using the ABI
3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA).
2.10.2. Methylation-speciﬁc PCR (MSP)
To analyze the methylation status of the MT1F gene, MSP analysis
was undertaken using the following primer sequences: sense, 5′-
AGGGATGGTTTGTGGTGTGTAGT-3′ and antisense, 5′-CCCAAACACA
AAACCCAACA-3′ for unmethylated reactions (312 bp), and sense, 5′-
ATGGTTCGCGGTGTGTAGC-3′ and antisense, 5′-CCAAACACGAAACCC
AACG-3′ for methylated reactions (307 bp). PCR conditions were as
follows: 95 °C for 5 min; 40 cycles of 94 °C for 30 s, 65 °C for 30 s
and 68 °C for 60 s; and a ﬁnal extension of 5 min at 68 °C. PCR prod-
ucts were separated by electrophoresis on 1.5% agarose gels.
2.10.3. LOH analysis
Two ﬂuorescence-labeled primers (Shanghai Biological Technolo-
gy Ltd, China) for polymorphic microsatellite markers located close to
the MT1F locus were used to analyze matched pairs of normal and
tumor DNA for LOH analysis. The following primer sequences were
used: D16S2878 sense, 5′-CCTATCCATTCCACATCTAAAC-3′ and D
16S2878 antisense 5′-CCTCTCAAAGTATGGGGATTAT-3′ (130 bp) and
D16S3008 sense, 5′-AACCACATGACAACTCGCCA-3′ and D16S3008 an-
tisense, 5′-CTTTGGGCGAAGCTAACATC-3′ (106 bp). Ampliﬁcation was
done in a 5-μL volume with 10 ng DNA, 10× standard buffer,
1.5 mmol/L MgCl2, 20 mmol/L deoxynucleotide triphosphates, 0.05
μL Hot-start Taq polymerase (Qiagen, Hilden, Germany) and
0.05 μmol/L of each primer. The cycling conditions were as follows:
an initial denaturation at 95 °C for 15 min; 95 °C for 30 s, 63–56 °C
for 1.5 min (0.5 °C decreased per cycle), 72 °C for 1 min; 30 cycles
each at 94 °C for 30 s, 56 °C for 1.5 min, 72 °C for 1 min, and a ﬁnal ex-
tension at 72 °C for 10 min. An ABI 3730 sequencer was used to
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each allele and calculating the allele ratio, LOH was determined when
the value of allele ratio≤0.67 or ≥1.5. A single fragment ampliﬁed
from normal DNA and those PCR reactions in which fragments were
not ampliﬁed were considered as non-informative.
Alleleratio ¼ heightof normalalleletwo=heightof normalalleleone
heightof tumoralleletwo=heightof tumoralleleone2.11. Statistical analysis
Data were expressed as means and standard deviations (SDs) for
continuous variables or frequencies and percentages for categorical
data. The Student's t test was used for comparisons of means between
two groups; the three-group comparisons were conducted using one
way analysis of variance (ANOVA). Multiple comparisons were per-
formed using the Bonferroni procedure with type-I error adjustment
for statistically signiﬁcant values. The associations between categori-
cal variable and outcome were determined using the Fisher's exact
test. The level of signiﬁcance was set at 0.05. Statistical analyses
were performed using SAS 9.1 (SAS Institute Inc., Cary, NC) statistical
software.Table 1
Downregulated gene expression in LOH loci.
LOH locia Gene
symbol
Chromosome location Fold-
changeb
p-Value
16q13.1 MT1F chr16:55249335–55250716 −3.7 0.004150
MT1G chr16:55258153–55259478 −3.9 0.004150
MT1X chr16:55273882–55275462 −3.3 0.037598
MT2A chr16:55199996–55200910 −3.3 0.001221
MT1E chr16:55216896–55218525 −3.7 0.067627
MT1H chr16:55261274–55262541 −3.8 0.067627
PLLP chr16:55847509–55876072 −1.7 0.046143
16q24.1 SPG7 chr16:88138143–88142270 −1.1 0.080566
COTL1 chr16:84599204–84651669 −2.7 0.432373
TCF25 chr16:88467507–88494703 −2.1 0.008057
HSD17B2 chr16:80626363–80689638 −6.7 0.633789
11p13 CD59 chr11:33686714–33714601 −2.2 0.001221
3q28–29 SST chr3:188869393–188870896 −3.3 0.601074
B3GNT5 chr3:184471286–184473866 −1.1 0.000244
4q34–35 HPGD chr4:175647784–175680550 −4 0.095215
FBXO8 chr4:175394386–175441386 −1 0.001221
6q25.2–27 VIP chr6:153113734–153122591 −5.9 0.828613
VIL2 chr6:159106767–159159196 −2.6 0.398926
TAGAP chr6:159375566–159376530 −1.6 0.095215
7p21–22 AGR2 chr7:16798790–16811222 −1.6 0.000244
SCIN chr7:12576536–12659753 −3.7 0.001953
BCMP11 chr7:16865561–16888137 −4.9 0.010742
7q21–22 ABCB1 chr7:86970275–86971055 −1.5 0.010742
CYP3A4 chr7:99193508–99219649 −1.6 0.149658
CYP3A7 chr7:99140595–99170757 −1.5 0.432373
CASD1 chr7:94002610–94024215 −1.6 0.001953
GNAI1 chr7:79602097–79685286 −2.1 0.246094
FZD1 chr7:90731718–90736068 −2.2 0.129639
HGF chr7:81166256–81237380 −2.9 0.432373
SRI chr7:87672365–87687322 −1.7 0.000244
SAMD9 chr7:92567100–92570485 −4.6 0.696289
RPIB9 chr7:87299096–87299547 −2.6 0.018555
LOC253012 chr7:92655834–92656398 −5.7 0.171387
PDK4 chr7:95050744–95052702 −3 0.001953
9p21–23 MOBKL2B chr9:27319128–27519779 −1.8 0.018555
CDKN2B chr9:21992898–21993475 −4.7 0.19458
LRRC19 chr9:26983587–26995670 −4.4 0.010742
a The LOH regions as reported previously [6].
b Cancer tissue versus normal tissue.3. Results
3.1. Genes downregulated in LOH loci
Analysis of downregulated genes mapping to the LOH loci was ac-
complished by combining the data from the LOH and the gene ex-
pression array; 37 genes were mapped to these LOH regions; the
fold-changes from array were shown in Table 1.
Because the LOH at 16q chromosome was observed in Chinese
colon cancer patients [7], candidate TSGs may exist in this region.
Colon cancer tissue was isolated from 40 patients and used for subse-
quent gene expression analysis. MT1F, MT1G, MT1X, and MT2A genes,
which are all located on chromosome 16q13.1, were all signiﬁcantly
downregulated in colon cancer specimens (all pb0.05; Table 1).
3.2. Reduced transcriptional expression of MT genes in colon cancer
To further conﬁrm whether MT isoforms were differentially
expressed in colon cancer as compared to adjacent normal mucosa,
their expression levels in 40 colon cancer samples were determined
using QRT-PCR. As compared to normal mucosa, MT mRNA expres-
sion levels of each isoform were downregulated in the majority
(>75%) of the colon cancer samples analyzed (Table 2, Fig. S1). Al-
though MT1F mRNA expression was downregulated, its expression
was not associated with clinicopathological features (Table S3).
Other MT isoforms were not associated with clinicopathological char-
acteristics too (data not shown).
3.3. Analysis of MT protein expression by TMA immunohistochemistry
To detect MT protein expression in colon cancer, immunohisto-
chemical analysis of TMAs was undertaken using an antibody that
recognizes both MT1 and MT2. Of the 203 normal mucosa specimens,
186 (91.6%) had positive MT expression, whereas the absence of MT
protein staining was evident in many colon cancer tumors (114/
203, 56.2%; Fig. 1). In addition, MT protein expression was decreased
in samples with downregulated MT isoform mRNA expression, sug-
gesting that MT gene downregulation correlated with decreased pro-
tein level. Downregulation of MT protein expression in tumor tissues
was conﬁrmed using Western blot analysis (Fig. S2).
Although downregulation of MT1F mRNA expression was not as-
sociated with clinicopathological features, reduced MT protein ex-
pression was signiﬁcantly associated with depth of tumor invasion
(pT stage), lymph node metastasis (pN stage), and AJCC stage
(p=0.048, 0.023 and 0.045, respectively). No correlations were
found between MT protein expression and age, gender, tumor loca-
tion, distant metastasis (M stage), histologic grade or vascular inva-
sion (Table S4).
3.4. Exogenous MT1F inhibits RKO cell survival, invasion and adhesion
Because the MT1F gene was downregulated in normal-adenoma–
carcinoma sequence of colon tissues [18], its mRNA expression wasTable 2
Frequency of MT isoform mRNA downregulation in 40 colon cancer tissues compared
with normal mucosa.
MT
isoform
Frequencies of transcriptional expression
Downregulated Nondownregulated
MT1E 32 (80.0%) 8 (20.0%)
MT1F 33 (82.5%) 7 (17.5%)
MT1G 32 (80.0%) 8 (20.0%)
MT1H 31 (77.5%) 9 (22.5%)
MT1X 30 (75.0%) 10 (25.0%)
MT2A 31 (77.5%) 9 (22.5%)
Data are represented as counts (percentages).
Fig. 1. Immunohistochemical staining of MT protein in normal colon mucosa (A) and cancerous tissues (B) on a TMA (400×). Insets depict the corresponding lower magniﬁcation
view (50×).
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LoVo cells as compared to the other cell lines (Fig. S3).
Because MT1F mRNA expression and MT protein expression were
undetectable in RKO cells, which have with the capacity to form col-
onies in agarose gel and tumors in nude mice, the RKO cell line was
selected for the subsequent in vitro experiments. In order to examine
the inﬂuence of MT1F expression on colon cancer cell growth, RKO
cells were transfected with an MT1F expression plasmid. Upregula-
tion of MT1F expression was conﬁrmed in transiently and stably
transfected cells (Fig. S4A and B, respectively).
Signiﬁcantly decreased proliferation of MT1F-transfected RKO
cells was observed after 2 to 6 days as compared to both control
groups (Fig. 2A). In addition, RKO colony formation was signiﬁcantly
decreased upon MT1F expression (pb0.05; Fig. 2B). Furthermore,
RKO cell apoptosis rate signiﬁcantly increased from 15.0% and 17.3%
among parental and empty vector-transfected cells, respectively to
28.2% in MT1F-transfected cells (pb0.05, Fig. 2C). Marked DNA lad-
ders were also observed in MT1F-overexpressing cells, and the
changes were not found in cells of other two groups (Fig. 2D). How-
ever, no differences in cell cycle distributions were observed (Fig.
S5). These results suggest that MT1F inhibits cell growth by inducing
RKO cell apoptosis.
The effect of MT1F expression on RKO cell invasion and adhesion
was also assessed. Cell migration and invasion were signiﬁcantly re-
duced in MT1F-transfected cells as compared to parental and empty
vector-transfected cells (pb0.05; Fig. 2E). In addition, decreased adhe-
sion to Collagen I and IV was observed in MT1F-expressing RKO cells
(pb0.05, respectively, Fig. 2F). These data suggest that MT1F could
have a potential role in the initial stages of colon cancer progression.
3.5. MT1F inhibits tumor growth in vivo
To evaluate the effect of MT1F on tumorigenesis in vivo, MT1F-
cDNA or empty vector-transfected RKO cells were subcutaneously
implanted in mice. The growth rate of MT1F-expressing tumors was
reduced as compared to control tumors. Speciﬁcally, the average
tumor size of MT1F-expressing tumors was reduced as compared to
empty vector-expressing tumors at day 21 (1.14±0.54 cm3 versus
2.89±0.64 cm3, respectively pb0.05, Fig. 3A). In addition, the aver-
age weight of MT1F-expressing tumors was reduced as compared to
controls (1.08±0.38 g versus 2.50±0.45 g, respectively, pb0.05,
Fig. 3B). These results reveal that MT1F can inhibit RKO tumor growth
in vivo.
3.6. High frequency of LOH at MT1F gene locus but not hypermethylation
in colon cancer tissues
Promoter hypermethylation, intragenic mutations, or LOH can in-
duce downregulation of certain genes [25]. Therefore, the role ofpossible CpG island methylation in the loss of MT1F expression in
colon cancer cells was assessed. A CG-rich region with 41 CpG sites
around the transcriptional start site of MT1F was observed (Fig. 4A).
BSP detection (Fig. S6) and MSP detection (Fig. S7) revealed that
MT1F gene was methylated in only LoVo and RKO cells, not in other
four cell lines. However, there was no MT1F hypermethylation in
colon cancerous tissue samples based onMSP detection (Fig. 4B), sug-
gesting that other mechanisms, such as genetic alterations, might in-
volve in silencing of MT1F in colon cancerous tissues.
As MT1F downregulation can occur without gene mutation [26],
the LOH status of the MT1F gene was assessed in colon cancer tissues
using two microsatellite markers, D16S2878 and D16S3008, which
were found on chromosome 16q13.1, ﬂanking the MT1F locus. In
the 40 pairs of colon cancer specimens, there were 35 and 34 infor-
mative cases at each of the D16S2878 and D16S3008 markers, respec-
tively (Table S1). Then, LOH at markers D16S2878 and D16S3008 was
observed in 40% (14 of 35) and 47.1% (16 of 34) of the samples, re-
spectively. Five cases exhibited LOH at both markers (Fig. 4C and D,
Table S1). Furthermore, 100% (25/25) LOH cases while only 53.8%
(7/13) non LOH cases showed downregulation of MT1F. MT1F down-
regulation was signiﬁcantly associated with LOH in colon cancer tis-
sues (pb0.001, Table 3). However, as with MT1F mRNA expression
(Table S3), no signiﬁcant correlation was found between MT1F LOH
status and clinicopathologic features of the patients (Table S5).
Taken together, these data indicate that LOH may be the principle
mechanism responsible for the inactivation of MT1F gene expression
in colon cancer tissues.
4. Discussion
In this study, we found that the downregulation of speciﬁcMT iso-
forms was observed in colon cancer. The transcriptional expression of
MT1F was inactivated by LOH in colon cancer tissues; CpG island
hypermethylation was also observed in poorly differentiated, MSI-
positive RKO and LoVo colon cancer cell lines but not in tumor tissues.
Because downregulation ofMT genes has been reported in several
tumors, their role as tumor suppressors in colon cancer was explored
in this study. Combination analysis of LOH and microarray data has
revealed several candidate TSGs [27,28]. Functional studies revealed
that MT genes might act as tumor suppressors in colon cancer. LOH
mediated MT downregulation in colon cancer tissues.
MT1F, MT1G, MT1X, and MT2A gene expression was signiﬁcantly
downregulated in colon cancerous tissues, which is in accordance
with previous reports [18,29]. Speciﬁcally, expression of the MT1F
gene gradually decreased from the benign to malignant phenotype
[18]. The dysregulation of MT genes could possibly relate to the em-
bryological origin of neoplastic lesion. The MT1F gene is often down-
regulated in endodermal hepatic and pharyngeal cancer cells, as well
as in mesodermal prostate cancer cells [8]. Although the MT1F gene
Fig. 2. The effect of MT1F expression on RKO cell proliferation (A), colony formation (B), apoptosis (C,D), migration and invasion (E), and adhesion (F). In panel D, lanes 1 to 4 were
DNA marker, RKO cells, empty vector and MT1F transfected cells, respectively. The experiments were repeated in triplicate. Differences among the three groups were analyzed by
ANOVA. Multiple comparisons were tested by Bonferroni adjustment with type-I error. Data represent means and SDs. In panel F, RKO cell adhesion to the following extracellular
matrix components was determined: FN, Fibronectin; COL I, Collagen I; COL IV, Collagen IV; LN, Laminin; and FB, Fibrinogen. *pb0.05, shows the difference between parental and
MT1F-transfected RKO cells. †pb0.05, shows the difference between vector control and MT1F-transfected cells.
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Fig. 3. Inhibition of RKO cell tumorigenicity upon MT1F expression. (A) The tumor vol-
ume from six mice was observed in each group every three days from day 4 to day 21.
(B) At day 21, the mice were sacriﬁced, and the tumor weights were measured. Data
represent means and SDs. *pb0.05, showed a signiﬁcant difference between MT1F-
and vector alone-transfected cells.
Table 3
The association between MT1F mRNA expression and LOH in colon cancer tissues.
Downregulation
of MT1F
No. of samplesa p-Value
LOH No LOH
(no. of cases) (no. of cases)
Present 25 (100%) 7 (53.85%) b0.001†
Absent 0 (0%) 6 (46.15%)
Data were represented as counts (percentages).
†pb0.05, showed a signiﬁcant association between the presence of MT1F
downregulation and LOH.
a Two samples without effective information of all markers D16S2878 and
D16S3008 were not included in analysis.
924 D.-W. Yan et al. / Biochimica et Biophysica Acta 1822 (2012) 918–926was obviously downregulated in endodermal colon cancers, its mRNA
levels were not associated with the clinicopathological characteristics
of the patients. MT protein was also signiﬁcantly decreased in tumor-
ous tissues compared with matched normal colonic mucosa, which is
in agreement with several previous reports [12–14]. Furthermore,Fig. 4. A representative illustration of LOH at MT1F gene locus but not hypermethylati
length=604 bp) in MT1F gene by using CpG island searcher (http://cpgislands.usc.edu) a
the transcriptional start site of MT1F. (B) The representative electrophoresis map of MSP p
2 markers together in the same CC tissues. Marker D16S2878, Allele Ratio=(T1:T2)/(N1:N
and consistent with the LOH criterion. (D) Marker D16S3008, the pattern of a single peak in
products; U: unmethylated products; T: tumor tissues; N: normal tissues.metallothionein expression was evenly distributed in the cytoplasm
and nuclei, which was similar to that previously reported [13,14,16],
Similar to other investigations [14,30,31], a signiﬁcant association be-
tween MT protein levels and pT, pN and AJCC stage was observed. In
premalignant high-grade dysplasia, reduced MT protein expression is
suggestive that it may be an early step in colon carcinogenesis
[32,33].
A role for MTs in colon cancer progression has yet to be elucidated.
Considering their anti-oxidant, anti-inﬂammatory and anti-
mutagenic properties, MT downregulation may increase susceptibili-
ty toxin-induced damage [34]. Indeed, MT-null mice had a higher rate
of induced carcinogenesis compared with wild-type mice [35–39]. In-
hibition of NF-κB activity by MTs may suppress cancer cell growth
and induce apoptosis [40]. MTs also reduce the expression of proteins
required for carcinogenesis, including cyclooxygenase-2, nitric oxide
synthase, tumor necrosis factor-α, interleukin (IL)-1β and IL-6 ex-
pression.8 Furthermore, MT directly interact with p53 and may alter
its activity through zinc exchange [41].
In the present study, restoration of MT1F gene expression in RKO
cells reduced both in vitro proliferation through increased apoptosison in colon cancer tissues. (A) The CpG island (%GC=64.6, Obs./Exp. CpG=0.652,
nd software MethPrimer (http://www.urogene.org/methprimer). The arrow indicated
roducts from colon cancerous tissues for methylation study of MT1F gene. (C) LOH on
2)=(5250:16,856)/(29,897:31,254)=0.33. The value of allele ratio is less than 0.67
tumor and two peaks in normal tissue ﬁts well for typical peak of LOH. M: methylated
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suppressor. This is consistent with Hecht et al. [42] where transfec-
tion of the MT1F gene into salivary gland cells from submandibular
tumors promoted morphologic differentiation in vitro and in vivo,
and reduced tumor growth in nude mice. Exogenous MTIF gene ex-
pression inhibited the growth and tumorigenicity of HepG2 liver can-
cer cells [26]. MT1F might induce apoptosis by inhibition of NF-κB
activity; however, the molecular mechanisms governing the effects
of MT1F expression on colon cancer cell growth and tumorigenicity
requires further exploration.
MT expression was signiﬁcantly reduced in the metastatic colon
cancer lesions and inversely correlated with CD44 expression [14].
Colon cancer cells with MT downregulation also gave rise to the he-
patic metastasis, suggesting that MTs may modulate the metastatic
process [15,43]. In line with those reports, restoration of MT1F ex-
pression inhibited RKO cell migration, invasion and adhesion in
vitro. Further studies are necessary to determine the mechanism by
which MT expression inﬂuences metastasis in vivo.
The mechanisms leading to MT mRNA downregulation in colon
cancer were explored in the present study; hypermethylation was as-
sociated with MT1F downregulation only in RKO and LoVo cell lines,
which is consistent with previous reports [44–48]. For example, CpG
hypermethylation of MT1E was present in endometrial cancer and
melanoma [44,45]; MT1G hypermethylation was reported in hepato-
blastoma, breast and lung cancers [46–48]. However, in our study, no
evidence of methylation was found in colon cancer tissues. It remains
possible that some parenchymal cells of a different subtype or miscel-
laneous mesenchymocytes were hypermethylated, but not others.
Moreover, it is possible that only one allele was methylated, thereby
affecting the results. Differences in MT1H, MT1X, and MT2A gene ex-
pression have been observed between microsatellite instability
(MSI) and microsatellite stability (MSS) colon cancer [49]. RKO and
LoVo cell lines are poorly differentiated and have MSI whereas
SW620 and HT29 are MSS and well differentiated [50]. Our results in-
dicated that MT1F mRNA expression in RKO and LoVo cell lines was
signiﬁcantly down-regulated with hypermethylation at its promoter
region in comparison to CW-2 and HT29 cell lines. Thus, downregula-
tion and hypermethylation of the MT1F gene might be associated
with MSI in colon cancer. These results are different from those
reported for MT2A in which no differences were observed in several
colon cancer cell lines [51]. Further studies are necessary to deter-
mine if the methylation status of MT1F is related to the differentiation
status of colon cancer cells.
Loss of MT expression may also be attributed to LOH [8]. Chromo-
somal LOH was associated with MT1F mRNA downregulation in colon
cancer tissues in the present study. Because MT1F gene downregula-
tion often occurs absent gene mutations in hepatocellular carcinoma
[26], the MTIF gene may be deleted through LOH; however, this has
to be conﬁrmed in further studies. Inactivation of a TSG typically
takes place in two steps: a small deletion or germline mutation inher-
ited from parents and a large deletion of part of a chromosome in so-
matic cells that involves a particular gene [52]. Detection of LOH can
help to understand the molecular mechanisms of tumor development
and provide important information about disease diagnosis and prog-
nosis [53]. MT1F gene LOH was more frequently observed in tumors
with a diameter less than 5 cm with a well differentiated grade and
histotype. Although the differences were not statistically signiﬁcant,
this trend suggested that MT1F LOH might be an early event in
colon cancer progression. As MT1F gene LOH was not present in a mi-
nority of colon cancerous tissues, further analysis of the downregula-
tion of MT genes in primary colon carcinomas is required.
The present study has limitations that warrant discussion. MT1F
was the only isoform analyzed. The effects of downregulation of the
other MT isoforms require further investigation. In addition, the
mechanism by which MT1F expression decreased tumor size was
not analyzed. Although increased RKO cell apoptosis was observedupon MT1F expression in vitro, it remains to be elucidated whether
the same effect is observed in vivo. Finally, the effects of MT1F expres-
sion were only analyzed in RKO cells. Determining the effects of MT1F
knockdown in cells that express high levels of MT1F expression, in-
cluding CW-2 and HCT116 cells, as well as normal cells is necessary
to support that the MT1F gene is a tumor suppressor; this will be de-
termined in further studies.
Taken together, the downregulation of speciﬁc MT isoforms was
observed in colon cancer. Loss of heterozygosity is main reason for
MT1F mRNA downregulation in colon cancer. A putative tumor sup-
pressor role for the MT1F isoform in colon cancer was observed. How-
ever, further explorations are required to fully elucidate the
molecular mechanisms governing MT gene dysregulation and its
role in colon cancer progression.
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